Compounds > topotecan
Page last updated: 2024-08-24

topotecan and caffeine

topotecan has been researched along with caffeine in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's5 (55.56)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ardelt, B; Darzynkiewicz, RJ; Darzynkiewicz, Z; Gong, J; Kapuscinski, J; Traganos, F1
Dai, W; Darzynkiewicz, Z; Halicka, HD; Huang, X; Kurose, A; Tanaka, T; Traganos, F1
Mullangi, R; Mustafa, S; Pasha, K; Srinivas, NR; Venkatesh, P1
Davies, DB; Evstigneev, MP; Evstigneev, VP; Mosunov, AA; Parkes, HG1

Reviews

1 review(s) available for topotecan and caffeine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

8 other study(ies) available for topotecan and caffeine

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
    Cancer research, 1993, Oct-01, Volume: 53, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; Caffeine; Camptothecin; Cell Cycle; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Topotecan; Tumor Cells, Cultured

1993
Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2005, Volume: 68, Issue:1

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle; Cell Cycle Proteins; Cell Nucleus; Cytoplasm; DNA-Binding Proteins; Flow Cytometry; Histones; HL-60 Cells; Humans; Immunohistochemistry; Interphase; Kinetics; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Serine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Topotecan; Tumor Suppressor Proteins

2005
Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?
    Xenobiotica; the fate of foreign compounds in biological systems, 2006, Volume: 36, Issue:12

    Topics: Acute Kidney Injury; Adenosine A1 Receptor Antagonists; Animals; Caffeine; Drug Interactions; In Vitro Techniques; Injections, Intravenous; Kidney; Male; Microsomes, Liver; Rats; Rats, Wistar; Topotecan; Uranyl Nitrate; Xanthines; Xenobiotics

2006
Quantification of the interceptor action of caffeine on the in vitro biological effect of the anti-tumour agent topotecan.
    European biophysics journal : EBJ, 2011, Volume: 40, Issue:8

    Topics: Antineoplastic Agents; Binding, Competitive; Caffeine; DNA; Humans; Models, Chemical; Topotecan

2011